Recording Date: March 7, 2019
Presenter: Josiah Allen

Abstract

Pharmacogenomic (PGx) testing is a relatively recent innovation in care and has brought with it the hope of utilizing genetic information to better tailor medical interventions. While the widespread use of PGx testing poses a significant potential benefit to the health system, our understanding of the cost-effectiveness of PGx testing is still maturing. Josiah's whitepaper, An Economic Evaluation of Pharmacogenomic Testing, covers current knowledge surrounding PGx testing with regard to cost-effectiveness and highlights where evidence clearly supports its use.

Key Takeaways:

  • Analysis of six patient-focused studies 
  • Relevance of PGx to significant patient populations
  • Cost-effectiveness and cost savings of genetically-guided strategies
  • Pharmacogenomics as a new standard of care for prescribers

About the Presenter

Josiash HeadshotJosiah Allen is the principal consultant at Medigenics Consulting.  For more than 10 years, Josiah has been a leader in the field of personalized medicine. He has led multiple scientific efforts including clinical research, product development, and clinical adoption & implementation for top-tier organizations such as the Mayo Clinic and Assurex Health. He has authored more than a dozen peer-reviewed publications in pharmacogenomics and has lectured extensively on clinical applications of pharmacogenomics to audiences of researchers, clinicians, and patients. He is a member of the American Society of Clinical Pharmacology and Therapeutics, the Clinical Pharmacogenetics Implementation Consortium, the Pharmacogenomics Research Network, and the Pharmacogenomics Access and Reimbursement Coalition.